These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9245486)

  • 21. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
    Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
    J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of adrenaline and glucocorticoids on monocyte cAMP-specific phosphodiesterase (PDE4) in a monocytic cell line.
    Delgado M; Fernández-Alfonso MS; Fuentes A
    Arch Dermatol Res; 2002 Jul; 294(4):190-7. PubMed ID: 12111350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis.
    Videla S; Vilaseca J; Medina C; Mourelle M; Guarner F; Salas A; Malagelada JR
    J Pharmacol Exp Ther; 2006 Feb; 316(2):940-5. PubMed ID: 16254133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of human cytokine production and effects of pharmacological agents in a heterologous system in vivo.
    Griswold DE; Hillegass LM; O'Leary-Bartus J; Lee JC; Laydon JT; Torphy TJ
    J Immunol Methods; 1996 Sep; 195(1-2):1-5. PubMed ID: 8814313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.
    Harada D; Tsukumo Y; Takashima Y; Manabe H
    Eur J Pharmacol; 2006 Feb; 532(1-2):128-37. PubMed ID: 16442096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of spasmogen-stimulated Ins(1,4,5)P3 generation and functional responses by selective inhibitors of types 3 and 4 phosphodiesterase in airways smooth muscle.
    Challiss RA; Adams D; Mistry R; Nicholson CD
    Br J Pharmacol; 1998 May; 124(1):47-54. PubMed ID: 9630342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor.
    Aoki M; Fukunaga M; Sugimoto T; Hirano Y; Kobayashi M; Honda K; Yamada T
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1142-9. PubMed ID: 11504812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential in vivo and in vitro bronchorelaxant activities of CP-80,633, a selective phosphodiesterase 4 inhibitor.
    Wright KF; Turner CR; Jayasinghe-Beck R; Cohen VL; Cheng JB; Watson JW
    Can J Physiol Pharmacol; 1997 Aug; 75(8):1001-8. PubMed ID: 9360015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of tumor necrosis factor-alpha production by interleukin-10 is enhanced by cAMP-elevating agents.
    Siegmund B; Eigler A; Moeller J; Greten TF; Hartmann G; Endres S
    Eur J Pharmacol; 1997 Feb; 321(2):231-9. PubMed ID: 9063693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacology of a novel, orally active PDE4 inhibitor.
    Dastidar SG; Ray A; Shirumalla R; Rajagopal D; Chaudhary S; Nanda K; Sharma P; Seth MK; Balachandran S; Gupta N; Palle V
    Pharmacology; 2009; 83(5):275-86. PubMed ID: 19321962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Critical time-window for the actions of adrenal glucocorticoids in behavioural sensitisation to cocaine.
    de Jong IE; de Kloet ER
    Eur J Pharmacol; 2009 Feb; 604(1-3):66-73. PubMed ID: 19121305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor.
    Claveau D; Chen SL; O'Keefe S; Zaller DM; Styhler A; Liu S; Huang Z; Nicholson DW; Mancini JA
    J Pharmacol Exp Ther; 2004 Aug; 310(2):752-60. PubMed ID: 15082748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of TNF-alpha production in human mononuclear cells by an adenosine kinase inhibitor.
    Eigler A; Matschke V; Hartmann G; Erhardt S; Boyle D; Firestein GS; Endres S
    J Leukoc Biol; 2000 Jul; 68(1):97-103. PubMed ID: 10914495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endotoxin potentiation of trichothecene-induced lymphocyte apoptosis is mediated by up-regulation of glucocorticoids.
    Islam Z; Moon YS; Zhou HR; King LE; Fraker PJ; Pestka JJ
    Toxicol Appl Pharmacol; 2002 Apr; 180(1):43-55. PubMed ID: 11922776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication.
    Angel JB; Saget BM; Walsh SP; Greten TF; Dinarello CA; Skolnik PR; Endres S
    AIDS; 1995 Oct; 9(10):1137-44. PubMed ID: 8519449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the phosphodiesterase inhibitor rolipram on streptococcal cell wall-induced arthritis in rats.
    Laemont KD; Schaefer CJ; Juneau PL; Schrier DJ
    Int J Immunopharmacol; 1999 Nov; 21(11):711-25. PubMed ID: 10576617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo.
    Yamamoto S; Sugahara S; Naito R; Ichikawa A; Ikeda K; Yamada T; Shimizu Y
    Eur J Pharmacol; 2006 Jul; 541(1-2):106-14. PubMed ID: 16780833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An interventional approach to block brain damage caused by Shiga toxin-producing Escherichia coli infection, by use of a combination of phosphodiesterase inhibitors.
    Okayama A; Mikasa K; Matsui N; Higashi N; Miyamoto M; Kita E
    J Infect Dis; 2004 Dec; 190(12):2129-36. PubMed ID: 15551211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells.
    Semmler J; Wachtel H; Endres S
    Int J Immunopharmacol; 1993 Apr; 15(3):409-13. PubMed ID: 8505151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide.
    Greten TF; Eigler A; Sinha B; Moeller J; Endres S
    Int J Immunopharmacol; 1995 Jul; 17(7):605-10. PubMed ID: 8586489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.